Company intelligence / Profile preview

Corcym

Ownership: Private
Employees: ~850
Development stage: Commercial

Overview

Corcym has a broad portfolio of FDA/EMA-approved patented products for structural heart diseases. Its Perceval system is the only sutureless aortic valve replacement system available in the US. The new Lancelot collapsible bovine pericardium/nitinol valve received FDA approval in 2025 for minimally invasive surgery. Clinical programs include the global MANTRA post-market study to monitor safety and performance across its product line[5][6].

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

No specific major pharma or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Corcym.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corcym.

Explore the full profile